Veru VERU
NASDAQ VERU
$2.64 +0.06 (+2.33%)
At close: Aug 21, 2026 · 4:00 PM EDT

Veru (VERU) Liabilities and Shareholders Equity (2010 - 2026)

Veru (VERU) posted quarterly Liabilities and Shareholders Equity of $43.1 million for Q1 2026, up 31.86% year-over-year from $32.7 million in Q1 2025, and down 9.43% quarter-over-quarter from $47.6 million in Q4 2025.

Veru (VERU) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Veru (VERU) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $43.1 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 31.86% year-over-year to $43.1 million; the TTM figure through Mar 2026 stood at $147.8 million (down 25.18% YoY), while the FY2025 annual figure was $29.8 million, down 50.62% from the prior year.
  • Liabilities and Shareholders Equity slipped to $43.1 million in Q1 2026 per VERU's latest filing, from $47.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $172.8 million in Q1 2022 and bottomed at $27.3 million in Q2 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $73.4 million across 5 years, with a median of $60.4 million in 2024.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 63.04% — and 2026, when it jumped 31.86%.
  • Veru's Liabilities and Shareholders Equity stood at $101.3 million in 2022, then declined by 20.45% to $80.6 million in 2023, then tumbled by 50.56% to $39.8 million in 2024, then gained by 19.43% to $47.6 million in 2025, then retreated by 9.43% to $43.1 million in 2026.
  • Business Quant data shows VERU's Liabilities and Shareholders Equity at $43.1 million in Q1 2026, $47.6 million in Q4 2025, and $29.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 Veru 60.85 Mn 35.06 Mn - 37.03 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 37.03 Mn
Mar 31, 2026 43.08 Mn
Dec 31, 2025 47.57 Mn
Sep 30, 2025 29.84 Mn
Jun 30, 2025 27.33 Mn
Mar 31, 2025 32.67 Mn
Dec 31, 2024 39.83 Mn
Sep 30, 2024 60.42 Mn
Jun 30, 2024 64.63 Mn
Mar 31, 2024 71.80 Mn
Dec 31, 2023 80.57 Mn
Sep 30, 2023 50.02 Mn
Jun 30, 2023 60.20 Mn
Mar 31, 2023 70.34 Mn
Dec 31, 2022 101.27 Mn
Sep 30, 2022 135.36 Mn
Jun 30, 2022 160.58 Mn
Mar 31, 2022 172.83 Mn
Dec 31, 2021 172.16 Mn
Sep 30, 2021 178.15 Mn